西酞普兰联合养血清脑颗粒治疗脑卒中后抑郁的临床观察

Clinical Observation of Citalopram Combined with Yangxue Qingnao Particle in the Treatment of Poststroke Depression

目的:观察西酞普兰联合养血清脑颗粒治疗脑卒中后抑郁的疗效和安全性。方法:选取120例确诊为脑卒中后抑郁的患者,按照随机数字表法均分为4组。对照组患者采用常规治疗;观察一组患者在对照组治疗基础上加服西酞普兰;观察二组患者在对照组治疗基础上加服养血清脑颗粒;观察三组在对照组治疗基础上加服西酞普兰和养血清脑颗粒。4组患者疗程均为6周。观察治疗前和治疗2、4、6周后患者的汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)评分,评定疗效和安全性。结果:治疗6周后,观察一组、观察二组、观察三组的总有效率分别为86.7%、83.3%、93.3%,对照组为56.7%,观察三组最高,对照组最低,分别与其他3组比较差异均有统计学意义(P<0.05),而观察一组与观察二组差异无统计学意义(P>0.05)。治疗前4组HAMD评分比较差异无统计学意义(P>0.05);观察一组、观察二组、观察三组治疗2、4、6周后HAMD评分均较治疗前显著降低,且治疗6周后观察三组的HAMD评分最低,与其他组比较差异有统计学意义(P<0.05)。4组的不良反应症状均较轻,发生率比较差异无统计学意义(P>0.05)。结论:西酞普兰联合养血清脑颗粒治疗脑卒中后抑郁的疗效显著,且安全性较高。

OBJECTIVE： To observe the therapeutic efficacy and safety of citalopram combined with Yangxue qingnao particle in the treatment of post-stroke depression. METHODS： 120 patients diagnosed as post-stroke depression in our hospital were randomly divided into 4 groups with 30 cases in each group. Control group received conventional treatment; observation group 1 was additionally given citalopram, observation group 2 Yangxue qingnao particles orally and observation group 3 citalopram and Yangxue qingnao particles on the basis of control group. Treatment course lasted for 6 weeks. Before treatment and 2, 4 and 6 weeks after treatment, Hamilton Depression Scale （HAMD） and TESS were observed to evaluate therapeutic efficacy and safety. RESULTS： Total effective rates of observation group 1, 2 and 3 were 86.7%, 83.3% and 93.3% 6 weeks after treatment, respectively; while that of control group was 56.7%; that of observation group 3 was the highest, and that of control group was the lowest and there was statistical significance between control group and other 3 groups （P〈0.05）; there was no statistical significance between observation group 1 and 2 （P〉0.05）. There was no statistical significance in HAMD score among 4 groups before treatment （P〉0.05）; HAMD score of observation group 1,2 and 3 decreased significantly after 2,4 and 6 weeks of treatment; that ofobservation group 3 was the lowest after 6 weeks of treatment; there was statistical significance （P〈0.05）. Side effects of 4 groups were mild, and there was no statistical significance in the incidence （P〉0.05）. CONCLUSIONS： Citalopram combined with Yangxue qingnao particle can improve post-stroke depression significantly with high safety.